Clinical Trial Update: A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing PT010, PT003, and PT009 with Symbicort in chronic dosing for chronic obstructive pulmonary disease (COPD) has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT003
• PT009
• PT010
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: COPD | Phase 3 | Status: COMPLETED | Results posted: 2020-12-24